Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|January 4, 2014
Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effectHåkon Reikvam, Jerome Tamburini, Silje Skrede, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2010
Feasibility of helical tomotherapy for debulking irradiation before stem cell transplantation in malignant lymphomaCyrus Chargari, Jean-Paul Vernant, Jerome Tamburini, et al.
Cancer Reports (Hoboken, N.J.)|October 16, 2024
Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma: Insights from real-life clinical practiceJasmine Mohamad, Antonin Bouroumeau, Thomas A McKee, et al.
Oncotargets and Therapy|February 23, 2017
FLT3 inhibitors: clinical potential in acute myeloid leukemiaMarie-Anne Hospital, Alexa S Green, Thiago T Maciel, et al.
Leukemia & Lymphoma|May 19, 2011
Leukemic phase of follicular lymphomas: an atypical presentationChadi Al-Nawakil, Olivier Kosmider, Marc-Henri Stern, et al.
Blood|September 20, 2007
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJerome Tamburini, Nicolas Chapuis, Valérie Bardet, et al.
Leukemia|February 4, 2023
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemiaClement Larrue, Sarah Mouche, Shan Lin, et al.
British Journal of Haematology|June 20, 2019
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective studyJohanna Mondesir, Anne-Sophie Alary, David Sibon, et al.
Blood|May 22, 2009
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemiaJerome Tamburini, Alexa S Green, Valerie Bardet, et al.
Haematologica|April 2, 2026
Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma: a case reportCarmen de Ramon Ortiz, Hana Abouzeid, Chiara De Bernardi, et al.
Pageof 5